JP2019532047A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019532047A5 JP2019532047A5 JP2019513967A JP2019513967A JP2019532047A5 JP 2019532047 A5 JP2019532047 A5 JP 2019532047A5 JP 2019513967 A JP2019513967 A JP 2019513967A JP 2019513967 A JP2019513967 A JP 2019513967A JP 2019532047 A5 JP2019532047 A5 JP 2019532047A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- administered
- virus
- antibody
- agent according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022150036A JP2022183170A (ja) | 2016-09-12 | 2022-09-21 | 癌を処置するためのアデノウイルスとチェックポイント阻害剤の組合せ |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16188301.2 | 2016-09-12 | ||
| EP16188301.2A EP3293201B1 (en) | 2016-09-12 | 2016-09-12 | Combining adenovirus and checkpoint inhibitors for treating cancer |
| PCT/FI2017/050645 WO2018046803A1 (en) | 2016-09-12 | 2017-09-11 | Combining adenovirus and checkpoint inhibitors for treating cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022150036A Division JP2022183170A (ja) | 2016-09-12 | 2022-09-21 | 癌を処置するためのアデノウイルスとチェックポイント阻害剤の組合せ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019532047A JP2019532047A (ja) | 2019-11-07 |
| JP2019532047A5 true JP2019532047A5 (enExample) | 2020-10-22 |
| JP7146739B2 JP7146739B2 (ja) | 2022-10-04 |
Family
ID=56926041
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019513967A Active JP7146739B2 (ja) | 2016-09-12 | 2017-09-11 | 癌を処置するためのアデノウイルスとチェックポイント阻害剤の組合せ |
| JP2022150036A Pending JP2022183170A (ja) | 2016-09-12 | 2022-09-21 | 癌を処置するためのアデノウイルスとチェックポイント阻害剤の組合せ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022150036A Pending JP2022183170A (ja) | 2016-09-12 | 2022-09-21 | 癌を処置するためのアデノウイルスとチェックポイント阻害剤の組合せ |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10940203B2 (enExample) |
| EP (2) | EP3783032A1 (enExample) |
| JP (2) | JP7146739B2 (enExample) |
| CN (1) | CN109715664A (enExample) |
| AU (1) | AU2017324482A1 (enExample) |
| DK (1) | DK3293201T3 (enExample) |
| ES (1) | ES2845690T3 (enExample) |
| HR (1) | HRP20210133T1 (enExample) |
| HU (1) | HUE053236T2 (enExample) |
| LT (1) | LT3293201T (enExample) |
| PL (1) | PL3293201T3 (enExample) |
| PT (1) | PT3293201T (enExample) |
| SI (1) | SI3293201T1 (enExample) |
| WO (1) | WO2018046803A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10350275B2 (en) * | 2013-09-21 | 2019-07-16 | Advantagene, Inc. | Methods of cytotoxic gene therapy to treat tumors |
| CN109789177A (zh) * | 2016-05-27 | 2019-05-21 | 德那翠丝有限公司 | 腺病毒和免疫调节剂组合治疗 |
| US20190275092A1 (en) | 2016-11-01 | 2019-09-12 | Dnatrix, Inc. | Combination therapy for treatment of brain cancers |
| GB201804473D0 (en) | 2018-03-21 | 2018-05-02 | Valo Therapeutics Oy | Modified oncolytic adenoviruses |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| CN114980920A (zh) | 2019-11-18 | 2022-08-30 | 詹森生物科技公司 | 基于突变体calr和jak2的疫苗及其用途 |
| WO2022009052A2 (en) | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| CN114426945B (zh) * | 2021-11-10 | 2024-08-23 | 西安交通大学医学院第一附属医院 | 胶质瘤类器官原代促活液、培养液及制备、培养方法 |
| CN121335710A (zh) * | 2023-04-07 | 2026-01-13 | 上海复诺健生物科技有限公司 | 重组溶瘤病毒与检查点抑制剂的组合用于治疗癌症 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2304281B1 (es) * | 2006-02-01 | 2009-08-12 | Dnatrix Inc. | Adenovirus oncoliticos para el tratamiento del cancer. |
| JP2012513209A (ja) | 2008-12-22 | 2012-06-14 | オンコス セラピュティックス オサケ ユキチュア | 腫瘍溶解アデノウイルスベクター並びに前記に関連する方法および使用 |
| FI20090030A0 (fi) * | 2009-02-02 | 2009-02-02 | Akseli Eetu Hemminki | Onkolyyttiset virukset |
| FI3381942T4 (fi) | 2012-08-30 | 2025-12-16 | Amgen Inc | Menetelmä melanooman hoitamiseksi herpes simplex -virusta ja immuuniaktivaation vapauttajaa käyttäen |
| US20150250837A1 (en) | 2012-09-20 | 2015-09-10 | Morningside Technology Ventures Ltd. | Oncolytic virus encoding pd-1 binding agents and uses of the same |
| US10350275B2 (en) | 2013-09-21 | 2019-07-16 | Advantagene, Inc. | Methods of cytotoxic gene therapy to treat tumors |
| KR20160137946A (ko) * | 2013-11-22 | 2016-12-02 | 디엔에이트릭스, 인코포레이티드 | 면역 세포 자극성 수용체 작용제(들)를 발현하는 아데노바이러스 |
-
2016
- 2016-09-12 LT LTEP16188301.2T patent/LT3293201T/lt unknown
- 2016-09-12 DK DK16188301.2T patent/DK3293201T3/da active
- 2016-09-12 PL PL16188301T patent/PL3293201T3/pl unknown
- 2016-09-12 PT PT161883012T patent/PT3293201T/pt unknown
- 2016-09-12 ES ES16188301T patent/ES2845690T3/es active Active
- 2016-09-12 EP EP20197744.4A patent/EP3783032A1/en not_active Withdrawn
- 2016-09-12 HU HUE16188301A patent/HUE053236T2/hu unknown
- 2016-09-12 SI SI201631076T patent/SI3293201T1/sl unknown
- 2016-09-12 EP EP16188301.2A patent/EP3293201B1/en active Active
-
2017
- 2017-09-11 AU AU2017324482A patent/AU2017324482A1/en not_active Abandoned
- 2017-09-11 US US16/330,274 patent/US10940203B2/en not_active Expired - Fee Related
- 2017-09-11 JP JP2019513967A patent/JP7146739B2/ja active Active
- 2017-09-11 WO PCT/FI2017/050645 patent/WO2018046803A1/en not_active Ceased
- 2017-09-11 CN CN201780055920.5A patent/CN109715664A/zh active Pending
-
2021
- 2021-01-05 US US17/141,463 patent/US11690913B2/en active Active
- 2021-01-26 HR HRP20210133TT patent/HRP20210133T1/hr unknown
-
2022
- 2022-09-21 JP JP2022150036A patent/JP2022183170A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018502120A5 (enExample) | ||
| UA118453C2 (uk) | Спосіб лікування пухлин у пацієнта | |
| CY1122143T1 (el) | Φαρμακευτικοι συνδυασμοι που περιλαμβανουν εναν αναστολεα της b-raf, εναν αναστολεα του egfr και προαιρετικα εναν αναστολεα της ρι3κ-αλφα | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| MX383866B (es) | Inhibidores de ezh2 para tratar linfomas. | |
| MX2020006042A (es) | Metodos de tratamiento de cancer de colon usando terapia combinada de inhibidor del objetivo mamifero de la rapamicina (mtor) en nanoparticulas. | |
| HRP20210200T1 (hr) | Kombinirana antitumorska imunoterapija | |
| JP2017516775A5 (enExample) | ||
| JP2019516711A5 (enExample) | ||
| MX385543B (es) | Uso de un anticuerpo biespecífico para tratar cáncer de linfocitos b. | |
| MX2016008362A (es) | Combinaciones farmaceuticas. | |
| WO2014127917A8 (en) | Combination of vaccination and inhibition of the pd-1 pathway | |
| JP2018508593A5 (enExample) | ||
| JP2016533366A5 (enExample) | ||
| MX2017014338A (es) | Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina. | |
| EA033448B1 (ru) | Композиция орлистата и акарбозы с модифицированным высвобождением для лечения ожирения и связанных метаболических нарушений | |
| JP2016519107A5 (enExample) | ||
| EP3442542A4 (en) | NANOPARTICLE, DOSAGE FORM WITH CONTROLLED RELEASE, AND METHOD FOR RELEASING AN IMMUNOTHERAPEUTIC | |
| JP2019530706A5 (enExample) | ||
| JP2017533220A5 (enExample) | ||
| MX2022011372A (es) | Composiciones de zinc-y-pga y metodos para tratar el cancer. | |
| EA202091112A1 (ru) | Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение | |
| HK1252514A1 (zh) | 包含与抗体组合施予的ido抑制剂的肿瘤治疗剂 | |
| Novello et al. | Motesanib plus carboplatin/paclitaxel in patients with advanced squamous non–small-cell lung cancer: results from the randomized controlled MONET1 study | |
| RU2020120876A (ru) | Фармацевтическая композиция, содержащая антагонист минералокортикоидных рецепторов, и ее применение |